TD Asset Management Inc. Has $68.76 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

TD Asset Management Inc. grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 452,240 shares of the pharmaceutical company’s stock after acquiring an additional 18,513 shares during the period. TD Asset Management Inc. owned 0.18% of Vertex Pharmaceuticals worth $68,759,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Vertex Pharmaceuticals by 0.8% in the 2nd quarter. BlackRock Inc. now owns 19,405,981 shares of the pharmaceutical company’s stock worth $2,500,849,000 after acquiring an additional 159,601 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Vertex Pharmaceuticals by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after buying an additional 504,982 shares during the period. Jennison Associates LLC grew its stake in shares of Vertex Pharmaceuticals by 19.0% in the 3rd quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after buying an additional 962,644 shares during the period. TIAA CREF Investment Management LLC grew its stake in shares of Vertex Pharmaceuticals by 28.1% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 2,077,303 shares of the pharmaceutical company’s stock valued at $267,702,000 after buying an additional 456,290 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,994,410 shares of the pharmaceutical company’s stock valued at $303,230,000 after buying an additional 12,454 shares during the period. 93.33% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Stuart A. Arbuckle sold 6,290 shares of the company’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $143.97, for a total transaction of $905,571.30. Following the completion of the transaction, the executive vice president now directly owns 116,952 shares of the company’s stock, valued at $16,837,579.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 218,519 shares of company stock valued at $31,819,910. Company insiders own 1.80% of the company’s stock.

A number of research firms have issued reports on VRTX. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Needham & Company LLC restated a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. DA Davidson began coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. Finally, BTIG Research began coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have issued a buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus price target of $173.15.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $138.79 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $71.46 and a 1 year high of $167.85. The stock has a market cap of $35,606.18, a price-to-earnings ratio of 234.65, a P/E/G ratio of 3.37 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. During the same period in the prior year, the business posted $0.16 earnings per share. The company’s revenue was up 39.7% on a year-over-year basis. analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “TD Asset Management Inc. Has $68.76 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/05/td-asset-management-inc-has-68-76-million-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply